Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent. 2010

Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
Departments of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn, USA. taijim@is.icc.u-tokai.ac.jp

In the present study, we tested the hypothesis that the renoprotective effect of an angiotensin receptor blocker depends on the angiotensin II type 1 (AT(1)) receptor on podocytes. For this purpose, we generated podocyte-specific knockout mice for the AT(1) gene (Agtr1a) and crossed with NEP25, in which selective podocyte injury can be induced by immunotoxin, anti-Tac(Fv)-PE38. Four weeks after the addition of anti-Tac(Fv)-PE38, urinary albumin:creatinine ratio was not attenuated in Agtr1a knockout/NEP25 mice (n=18) compared with that in control NEP25 mice (n=13; 8.08+/-2.41 in knockout versus 4.84+/-0.73 in control). Both strains of mice showed similar degrees of sclerosis (0.66+/-0.17 versus 0.82+/-0.27 on a 0 to 4 scale) and downregulation of nephrin (5.78+/-0.45 versus 5.65+/-0.58 on a 0 to 8 scale). In contrast, AT(1) antagonist or an angiotensin I-converting enzyme inhibitor, but not hydralazine, remarkably attenuated proteinuria and sclerosis in NEP25 mice. Moreover, continuous angiotensin II infusion induced microalbuminuria similarly in both Agtr1a knockout and wild-type mice. Thus, angiotensin inhibition can protect podocytes and prevent the development of glomerulosclerosis independent of podocyte AT(1). Possible mechanisms include inhibitory effects on AT(1) of other cells or through mechanisms independent of AT(1). Our study further demonstrates that measures that directly affect only nonpodocyte cells can have beneficial effects even when sclerosis is triggered by podocyte-specific injury.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
September 2011, Journal of cardiology,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
July 2013, Journal of medical case reports,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
June 2005, Clinical and investigative medicine. Medecine clinique et experimentale,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
September 2021, Obesity (Silver Spring, Md.),
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
July 2006, Journal of the American Society of Nephrology : JASN,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
June 2018, Acta biochimica et biophysica Sinica,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
September 2012, Nihon rinsho. Japanese journal of clinical medicine,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
April 2008, Experimental neurology,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
April 2011, The American journal of pathology,
Taiji Matsusaka, and Takako Asano, and Fumio Niimura, and Masaru Kinomura, and Akihiro Shimizu, and Ayumi Shintani, and Ira Pastan, and Agnes B Fogo, and Iekuni Ichikawa
July 2006, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!